Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein

Journal of Virology

Volumn 74, Issue 17, 2000, Pages 7922-7935

  Edinger, A L ^a   Ahuja, M ^a   Sung, T ^a   Baxter, K C ^a   Haggarty, B ^a   Doms, R W ^a   Hoxie, J A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 140; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; BINDING SITE; CELL FUSION; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTER; HYBRIDOMA; IMMUNIZATION; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; SIMIAN IMMUNODEFICIENCY VIRUS; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; BINDING, COMPETITIVE; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FLOW CYTOMETRY; GENE PRODUCTS, ENV; HIV ENVELOPE PROTEIN GP120; IMMUNIZATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; RECEPTORS, CCR5; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL ENVELOPE PROTEINS;

EID: 0033894950     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.17.7922-7935.2000     Document Type: Article

References (92)

1. Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor
2. Genotypic selection of simian immunodeficiency virus in macaque infants infected transplacentally
3. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
4. Specificity and neutralizing capacity of three monoclonal antibodies produced against the envelope glycoprotein of simian immunodeficiency virus isolate 251
5. Production and characterization of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins
6. Identification of a neutralizing domain in the external envelope glycoprotein of simian immunodeficiency virus
7. A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism
8. Antigenic implications of human immunodeficiency virus type-1 envelope quaternary structure: Oligomer-specific and -sensitive monoclonal antibodies
9. Identification of amino acids in the V3 region of gp120 critical for virus neutralization by human HIV-1-specific antibodies
10. A vaccine for HIV type 1: The antibody perspective
11. The antibody response in HIV-1 infection
12. Why do we not have an HIV vaccine and how can we make one?
13. Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection?
14. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
15. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein
16. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage
17. Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals
18. Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by super-infection of nonproductively infected cell lines with recombinant luciferase-encoding viruses
19. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes
20. The simian immunodeficiency viruses
21. International collaboration comparing neutralization and binding assays for monoclonal antibodies to simian immunodeficiency virus
22. Generation of recombinant vaccinia viruses
23. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities
24. Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains
25. Use of GPR1, GPR15, and STRL33 as coreceptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelope proteins
26. CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain
27. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
28. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4
29. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex
30. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120
31. Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: Recovery from a long-term-nonprogressor SIV-infected macaque
32. Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus
33. Relation of phenotype evolution of HIV-1 to envelope V2 configuration
34. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor
35. The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins
36. A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3
37. Stable exposure of the core-ceptor-binding site in a CD4-independent HIV-1 envelope protein
38. Hypothetical assignment of intrachain disulfide bonds for HIV-2 and SIV envelope glycoproteins
39. The principle neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1
40. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: Inverse relationship of degree of protection with level of attenuation
41. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans
42. Neutralising epitopes of simian immunodeficiency virus envelope glycoprotein
43. Production and characterization of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins
44. Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies
45. The 'V3' domain is a determinant of simian immunodeficiency virus cell tropism
46. Strain-specific neutralizing determinant in the transmembrane protein of simian immunodeficiency virus
47. Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization
48. Biological, molecular, and structural analysis of a cytopathic variant from a molecularly cloned simian immunodeficiency virus
49. A single amino acid change in the cytoplasmic domain of SIVmac transmembrane molecule increases envelope glycoprotein expression on cells and virions
50. Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity
51. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
52. Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus
53. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells
54. Genetic and biological comparisons of pathogenic and nonpathogenic molecular clones of simian immunodeficiency virus (SIVmac)
55. CD4-independent binding of SIV gp120 to rhesus CCR5
56. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
57. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
58. Neutralizing monoclonal antibody against an external envelope glycoprotein (gp110) of SIVmac251
59. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120
60. Interactions among HIV gp120, CD4, and CXCR4: Dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH- and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies
61. HIV-1 neutralizing antibodies: How full is the bottle?
62. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans
63. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies
64. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: Human immune response to the V1 and V2 domains
65. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1
66. Variation in simian immunodeficiency virus Env is confined to V1 and V4 during progression to simian AIDS
67. The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope
68. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity
69. The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity
70. Antibody neutralization of HIV-1
71. Prevention of HIV-2 and SIVsm infection by passive immunization in cynomlgus monkeys
72. A role for carbohydrates in immune evasion in AIDS
73. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
74. Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants
75. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer
76. An internalization signal in the simian immunodeficiency virus transmembrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surface
77. Expression and coreceptor activity of STRL33 on primary peripheral blood lymphocytes
78. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
79. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein
80. Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques
81. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein
82. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding
83. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly neutralizing human monoclonal antibody
84. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5
85. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage
86. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
87. A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody
88. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5
89. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens
90. Production of monoclonal antibodies
91. Neutralization of SIVmac239/17E in lymphocyte cultures involves virus strain-specific linear and conformational epitopes encoded by different regions of the env gene including the 'V3' domain